Slingshot members are tracking this event:

Pfizer (PFE) And Lilly (LLY) Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab at 16-weeks For The Treatment Of Osteoarthritis (OA) Pain

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Clinical Data Preliminary safety data showed that tanezumab was generally well tolerated, with approximately 1% of patients discontinuing treatment due to adverse events. Rapidly progressive osteoarthritis was observed in tanezumab-treated patients at a frequency of less than 1.5%, and was not observed in the placebo arm. There were no events of osteonecrosis observed in the trial. No new safety signals were identified.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 18, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Tanezumab, Osteoarthritis Pain, Subcutaneous Administration, Phase 3 Top Line Results, Positive Phase 3 Topline Results